DiNardo, C. D., Marvin-Peek, J., Loghavi, S., Takahashi, K., Issa, G. C., Jen, W., Daver, N. G., Reville, P. K., Short, N. J., Sasaki, K., Mullin, J. K., Bradley, C. A., Borthakur, G., Maiti, A., Alvarado, Y., Pemmaraju, N., Abbas, H. A., Hammond, D. E., Haddad, F., Bravo, G. M., Chien, K. S., Yilmaz, M., Kornblau, S. M., Jabbour, E., Ravandi, F., Kadia, T., Garcia-Manero, G., Konopleva, M. Y., Kantarjian, H. M. (2025). Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00640